MEXICO
CITY, May 7, 2024 /PRNewswire/ -- Mexico's pharmaceutical and personal care
industry is undergoing significant changes with the strategic moves
announced by Genomma Lab International, S.A.B. de C.V. (B.M.V.:
LABB) regarding its agreement to redeem capital in Marzam.
The pharmaceutical product distributor has been advancing its
strategy of divesting non-essential assets to focus on its core
brands and businesses. Its subsidiary Gibart, S.A. de C.V.,
currently holds a minority stake in Marzam, which is deemed
non-essential to the company's long-term strategy.
During several months of meticulous evaluation, proposals were
received to acquire majority stakes in Marzam. However, none met
the majority shareholders and controller's requirements of Marzam,
Moënch Cooperatief, U.A.
In response to this scenario, Luis
Doporto Alejandre has signed a definitive agreement to
increase Marzam's capital, with the aim of strengthening its
position in drug distribution and capitalizing on market
opportunities.
This strategic move reflects Marzam's commitment to resource
optimization and its firm intention to strengthen its position in
key sectors of the industry.
As an integral part of this agreement, Gibart has consented to
the capital increase while simultaneously commencing the reduction
of its shareholding in Marzam, which aligns with Genomma Lab's
strategy to divest non-essential assets.
This significant step in restructuring Marzam's operations is a
testament to its commitment to continued growth and market
leadership. It paves the way for a more streamlined and efficient
future.
Marzam aims to focus on its key assets to drive growth
and maximize value for all parties involved. The restructuring
agreement signed by Marzam represents a strategic step in this
direction.
Consolidating a capital increase is essential to strengthen its
presence in the drug distribution sector and capitalize on emerging
market opportunities.
The signing of this agreement implies that Gibart, a subsidiary
of Genomma Lab, has approved the capital increase while agreeing to
initiate the reduction of its shareholding in Marzam.
Both companies are subject to customary conditions for such
transactions and, once completed, are expected to strengthen their
position in the market further.
This strategic approach reflects Genomma Lab's and Marzam's
commitment to resource optimization and value generation in
Mexico's pharmaceutical and
personal care industries.
View original
content:https://www.prnewswire.com/news-releases/marzams-new-strategy-will-focus-on-strengthening-the-companys-position-within-pharmaceutical-sector-302138999.html
SOURCE Marzam